Investigation of the combination of the novel antibacterial agents (Combiotics) with azithromycin on Pseudomonas aeruginosa mice model lung infection

Pseudomonas aeruginosa is a common cause of infection in cystic fibrosis patients globally. However, the growing antibiotic resistance and the high cost of developing new antimicrobials emphasize the need for alternative approaches. While macrolide therapy has shown benefits, resistance to this treatment is on the rise, indicating the necessity for new agents. Plant-based compounds (PBCs), are being explored as a source of new antimicrobials due to their low toxicity and advantageous properties. In addition, metal-based antimicrobial agents (MABs) have been studied as effective infection control strategies. The Turner group has researched MBAs’ mechanisms, tolerance, and toxicity and the synergies between novel organic antimicrobials and metalloids. Metalloid and plant-based compounds also have demonstrated anti-inflammatory and antioxidant effects, which are crucial in respiratory infections. Therefore, the intern will focus on evaluating the combination effect of MBAs with different antimicrobials in a triple combination against P. aeruginosa, which has not yet been established.

Faculty Supervisor:

Raymond Turner

Student:

Partner:

Ahvaz Jundishapur University of Medical Sciences

Discipline:

Life Sciences

Sector:

Pharmaceuticals; Health and Related Sciences & Technology

University:

University of Calgary

Program: